21 U.S.C. § 331

21 U.S.C. § 331 is a statutory provision within Title 21 that enumerates prohibited acts concerning the distribution, introduction, and adulteration of articles related to food and drugs in interstate commerce. Enacted as part of broader federal statutory reform in the late 1930s, the section functions as a central enforcement hook empowering administrative and criminal remedies administered by Food and Drug Administration authorities and litigated in federal courts such as the United States District Court and the United States Court of Appeals for the D.C. Circuit.

Text of the Statute

The text lists discrete prohibitions including introduction of misbranded or adulterated articles into interstate commerce, false statements on labeling, distribution of unapproved new drugs, and failure to comply with prescribed standards. The statutory language operates in tandem with provisions in Federal Food, Drug, and Cosmetic Act and cross-references other federal enactments enforced by the Food and Drug Administration, the Department of Justice, and administrative tribunals.

Scope and Prohibited Acts

The provision proscribes acts such as introducing into interstate commerce any article that is adulterated or misbranded, distributing unapproved new drugs, making false statements about products, and failing to adhere to prescribed manufacturing standards. The reach implicates manufacturers like Pfizer, Johnson & Johnson, and Pfizer–BioNTech collaborators when products traverse state lines, implicates distributors such as McKesson Corporation and Cardinal Health, and affects retailers including Walmart and CVS Health. The prohibition extends to labeling practices that implicate trademarks or claims tied to entities like Mayo Clinic or Johns Hopkins Hospital when presented in interstate commerce. The statute also captures importation scenarios involving customs interactions with United States Customs and Border Protection and adjudication by the United States Court of International Trade.

Enforcement and Penalties

Enforcement is carried out administratively by the Food and Drug Administration and criminally by the Department of Justice, with civil remedies pursued in federal courts including the United States District Court for the Southern District of New York and the United States District Court for the District of Columbia. Penalties may include injunctions, seizure, condemnation, fines, and imprisonment under statutes enforced by agencies such as the Federal Trade Commission when deceptive practices overlap. Enforcement actions can involve agents from Federal Bureau of Investigation task forces in complex fraud matters and coordination with state attorneys general such as those from California and New York in multi-jurisdictional cases. Remedies have been sought against firms like Teva Pharmaceutical Industries and GlaxoSmithKline in litigation addressing misbranding or adulteration claims.

Judicial Interpretation and Key Cases

Courts have interpreted the provision in cases that elucidate standards for "adulteration," "misbranding," and what constitutes interstate commerce. Landmark litigation includes decisions by the Supreme Court of the United States that clarified federal preemption principles and statutory interpretation under Title 21, as well as appellate rulings from the United States Court of Appeals for the Second Circuit, the United States Court of Appeals for the Ninth Circuit, and the United States Court of Appeals for the Federal Circuit. Notable litigants and parties have included United States of America v. major manufacturers and distributor defendants, with significant opinions affecting Food and Drug Administration authority and labeling jurisprudence. Cases involving agencies like the Environmental Protection Agency and precedents from the Administrative Procedure Act context have also influenced construing enforcement scope and due process protections.

Regulatory Implementation and FDA Guidance

Regulatory implementation is executed through regulations codified in the Code of Federal Regulations and guidance documents issued by the Food and Drug Administration. The FDA issues guidance documents, warning letters, and compliance policy statements that operationalize the statute for stakeholders including pharmaceutical firms such as Eli Lilly and Company and device manufacturers like Medtronic. Implementation frequently involves coordination with standards-setting bodies such as the United States Pharmacopeia and international organizations including the World Health Organization and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Guidance addresses topics from current good manufacturing practice expectations to labeling requirements, with enforcement discretion applied in contexts involving public health emergencies declared by officials like the Secretary of Health and Human Services.

Category:United States federal criminal law